Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
cbdMD ( (YCBD) ) has issued an update.
On May 16, 2025, cbdMD, Inc.’s board of directors issued 1,572 restricted stock units to each independent and non-management employee director as compensation for their services starting April 11, 2025. These units will vest quarterly through March 31, 2026, under the company’s equity compensation plans. Additionally, the board approved annual cash retainers and additional fees for various committee roles, reflecting a structured compensation approach for its directors.
The most recent analyst rating on (YCBD) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on cbdMD stock, see the YCBD Stock Forecast page.
Spark’s Take on YCBD Stock
According to Spark, TipRanks’ AI Analyst, YCBD is a Underperform.
The overall score for cbdMD is driven by significant financial challenges, including negative cash flows and high leverage. While the earnings call showed some positive steps in restructuring and cost reduction, the technical analysis suggests ongoing bearish momentum. Valuation concerns persist with a negative P/E ratio, and the lack of dividend yield may deter income investors.
To see Spark’s full report on YCBD stock, click here.
More about cbdMD
cbdMD, Inc. operates in the wellness industry, primarily focusing on producing and selling CBD-based products. The company targets consumers seeking natural alternatives for health and wellness.
Average Trading Volume: 123,282
Technical Sentiment Signal: Sell
Current Market Cap: $8.55M
Find detailed analytics on YCBD stock on TipRanks’ Stock Analysis page.